Johnson & Johnson, a household name in healthcare, reported a solid start to 2025 with a 2.4% increase in first-quarter sales, reaching $21.9 billion. The company's operational growth stood at 4.2%, and even after adjustments, a healthy 3.3% rise was observed. Earnings per share (EPS) saw a significant jump to $4.54, buoyed by the reversal of special charges, with adjusted EPS also climbing to $2.77, marking a 2.2% increase.

The company has once again demonstrated its knack for navigating choppy waters, as its revenue and profit surpassed Wall Street's expectations. The healthcare giant's robust performance was largely driven by its cancer drug sales, even as it braces for the impact of trade tariffs introduced by the Trump administration.

In a move that signals confidence, J&J has upped its 2025 sales forecast by $700 million, thanks to the addition of the schizophrenia drug Caplyta to its lineup. It now projects 2025 sales between $91.6 billion and $92.4 billion, up from the previous range of $90.9 billion to $91.7 billion.

However, the company has kept its profit forecast steady, factoring in the financial hit from tariffs and the dilution effects of its $14.6 billion acquisition of neurological drugmaker Intra-Cellular.

J&J is the first major healthcare player to report earnings since the Trump administration's tariff proposals, which target trade partners like China—a crucial supplier of raw materials for the pharmaceutical and medical device sectors. The White House is also investigating pharmaceutical imports, citing national security concerns over foreign medicine production. This is why despite better-than-expected earnings, J&J's stock dipped by 0.5% at the open.

Chief Financial Officer Joe Wolk noted that the profit outlook includes an expected $400 million tariff-related cost in the medical device segment starting in the second quarter. This estimate considers existing tariffs on China, Mexico, and Canada, despite a temporary 90-day reprieve on some duties. 

Strong innovation

The quarter was marked by notable advancements in  the company's product pipeline. The company secured approval for TREMFYA for the treatment of Crohn’s disease and delivered promising survival data in non-small cell lung cancer with RYBREVANT/LAZCLUZE. Additionally, the initiation of clinical trials for OTTAVA, a general surgery robotic system, signaled Johnson & Johnson's continued investment in cutting-edge medical technology.

In a strategic expansion of its neuroscience portfolio, Johnson & Johnson completed the acquisition of Intra-Cellular Therapies, which brought CAPLYTA into its fold. Despite the additional costs from tariffs and the dilutive impact of the acquisition, the company has maintained its full-year adjusted reported EPS outlook, projecting a 6.2% growth at the mid-point.

Chairman and Chief Executive Officer Joaquin Duato expressed confidence in the company's diversified portfolio and innovation trajectory, which has been further solidified by the recent acquisition. "Our strong operational sales growth reinforces our confidence in the 2025 guidance," Duato said. "We are poised for continued growth, especially as we leverage our digital and data capabilities."

The company's financial health was reflected across its regional sales, with a 5.9% operational increase in the U.S. and a 2.1% rise internationally when adjusted for currency fluctuations. The Innovative Medicine segment reported a 4.2% operational growth, driven by key pharmaceuticals in Oncology, Immunology, Neuroscience, and Cardiovascular/Metabolism/Other. The MedTech segment also saw a 4.1% operational growth, thanks to contributions from acquisitions and strong performance in Cardiovascular and General Surgery, though partially offset by challenges in Orthopaedics.